▶ GLP-1 / GLUCAGON DUAL AGONIST · SUBTOPIC · SAFETY PROFILE

GLP-1 / GLUCAGON DUAL AGONIST Safety Profile

For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of GLP-1 / GLUCAGON DUAL AGONIST.

OBSERVED ADVERSE EVENTS IN LITERATURE

The following adverse events have been observed in trials or animal studies of GLP-1 / GLUCAGON DUAL AGONIST. Severity, frequency, and attribution depend on the source publication.

GI: nausea, vomiting, diarrhea
Injection-site reactions
Tachycardia (modest)

DRUG INTERACTIONS

The following interactions are reported in or theorised from the published mechanism for GLP-1 / GLUCAGON DUAL AGONIST.

Glucagonergic effects may interact with sulfonylureas/insulin

CONTRAINDICATIONS REPORTED IN LITERATURE

Contraindications recorded for GLP-1 / GLUCAGON DUAL AGONIST in the published record:

History of MTC or MEN2

FDA REGULATORY STATUS

Investigational. Phase 3 SYNCHRONIZE-1/2 obesity trials enrolling.

WADA REGULATORY STATUS

Not currently listed on the WADA Prohibited List.

SAFETY Q+A FROM LITERATURE

▶ Is the GLP-1 / glucagon dual agonist FDA-approved?

Not yet as of 2026-05. Phase 3 SYNCHRONIZE-1 and SYNCHRONIZE-2 trials for obesity are enrolling.

CITED LITERATURE

The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.

Le Roux CW, et al.. Glucagon and GLP-1 receptor dual agonist the GLP-1 / glucagon dual agonist for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024. PMID 38219768. link

◀ GLP-1 / GLUCAGON DUAL AGONIST OVERVIEW MECHANISM ▶DOSING LITERATURE ▶

▶ LAST UPDATED · 2026-05-19